RxDoctor Payments Data

Ernest Waller, MD

Pulmonary Disease · Maryville, TNNPI 1427047745

Payments from drug & device makers

$14,123in general payments, 2019–2025

Across 441 payments — averaging $32.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$6K
  • AstraZeneca$2K
  • Actelion Pharmaceuticals US, Inc.$1K
  • Insmed, Inc.$867
  • GSK$825
  • Boehringer Ingelheim$759
  • plus $3K from 37 others

What the payments were for

  • Travel & lodging$2,58318%
  • Food & beverage$8,47560%
  • Education$3,06522%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,123 in reported general payments places this provider in the 75th percentile of 339 pulmonary disease providers in Tennessee.

See all pulmonary disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$147,151
Medicare patients
339
Services billed
1,869

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate14$184,497
Trelegy ElliptaFluticasone/Umeclidin/Vilanter173$145,078
Spiriva RespimatTiotropium Bromide125$105,239
Dupixent PenDupilumab23$84,376
XolairOmalizumab17$66,693
Breo ElliptaFluticasone/Vilanterol122$53,233
NucalaMepolizumab12$51,363
Stiolto RespimatTiotropium Br/Olodaterol Hcl39$28,344
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$27,478
SymbicortBudesonide/Formoterol Fumarate59$19,674
EliquisApixaban19$16,043
Arnuity ElliptaFluticasone Furoate46$14,221
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$10,200
Albuterol Sulfate HfaAlbuterol Sulfate214$6,521
Incruse ElliptaUmeclidinium Bromide11$3,896

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$759$318,079178 claims
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Arnuity Ellipta, Anoro Ellipta$825$277,991382 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,630$47,15292 claims
PfizerEliquis$16$16,04319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 339 pulmonary disease providers in Tennessee.

Other pulmonary disease in Maryville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →